Dipeptidyl peptidase IV inhibitor treatment stimulates β-cell survival and islet neogenesis in streptozotocin-induced diabetic rats

J. Andrew Pospisilik, Jennifer Martin, Timothy Doty, Jan A. Ehses, Nathalie Pamir, Francis C. Lynn, Shalea Piteau, Hans Ulrich Demuth, Christopher H.S. McIntosh, Raymond A. Pederson

Research output: Contribution to journalArticlepeer-review

328 Scopus citations


Recent studies into the physiology of the incretins glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) have added stimulation of β-cell growth, differentiation, and cell survival to well-documented, potent insulinotropic effects. Unfortunately, the therapeutic potential of these hormones is limited by their rapid enzymatic inactivation in vivo by dipeptidyl peptidase IV (DP IV). Inhibition of DP IV, so as to enhance circulating incretin levels, has proved effective in the treatment of type 2 diabetes both in humans and in animal models, stimulating improvements in glucose tolerance, insulin sensitivity, and β-cell function. We hypothesized that enhancement of the cytoprotective and β-cell regenerative effects of GIP and GLP-1 might extend the therapeutic potential of DP IV inhibitors to include type 1 diabetes. For testing this hypothesis, male Wistar rats, exposed to a single dose of streptozotocin (STZ; 50 mg/kg), were treated twice daily with the DP IV inhibitor P32/98 for 7 weeks. Relative to STZ-injected controls, P32/98-treated animals displayed increased weight gain (230%) and nutrient intake, decreased fed blood glucose (∼26 vs. ∼20 nmol/l, respectively), and a return of plasma insulin values toward normal (0.07 vs. 0.12 mmol/l, respectively). Marked improvements in oral glucose tolerance, suggesting enhanced insulin secretory capacity, were corroborated by pancreas perfusion and insulin content measurements that revealed two- to eightfold increases in both secretory function and insulin content after 7 weeks of treatment. Immunohistochemical analyses of pancreatic sections showed marked increases in the number of small islets (+35%) and total β-cells (+120%) and in the islet β-cell fraction (12% control vs. 24% treated) in the treated animals, suggesting that DP IV inhibitor treatment enhanced islet neogenesis, β-cell survival, and insulin biosynthesis. In vitro studies using a β-(INS-1) cell line showed a dose-dependent prevention of STZ-induced apoptotic cell-death by both GIP and GLP-1, supporting a role for the incretins in eliciting the in vivo results. These novel findings provide evidence to support the potential utility of DP IV inhibitors in the treatment of type 1 and possibly late-stage type 2 diabetes.

Original languageEnglish (US)
Pages (from-to)741-750
Number of pages10
Issue number3
StatePublished - Mar 1 2003
Externally publishedYes


  • DP IV, dipeptidyl peptidase IV
  • GIP, glucose-dependent insulinotropic polypeptide
  • GLP-1, glucagon-like peptide-1
  • IDGTT, intraduodenal glucose tolerance test
  • IR, immunoreactive
  • OGTT, oral glucose tolerance test
  • PDX-1, pancreatic-duodenum homeobox-1

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Dipeptidyl peptidase IV inhibitor treatment stimulates β-cell survival and islet neogenesis in streptozotocin-induced diabetic rats'. Together they form a unique fingerprint.

Cite this